Slide 1: Corporate presentation
Corporate presentation September 2016 For personal use only David Burton – Chairman, CEO dburton@compumedics.com.au David Lawson – Director, CFO dlawson@compumedics.com.au Sleep Diagnostics & Treatment - Neuro Diagnostics - Brain Research - Ultrasonic Blood Flow Monitoring 1
Slide 2: AGM Agenda
AGM Agenda For personal use only Meeting Opens Ordinary Business Chairman's Address Meeting Closes 2
Slide 3: Ordinary Business
Ordinary Business For personal use only Item 1 Financial Statements and Reports Item 2 Election of a Director – Tucson Dunn Item 3 Re-election of Director – Alan Anderson Item 4 Adoption of Remuneration Report (non-binding resolution) 3
Slide 4: Who is Compumedics?
Who is Compumedics? For personal use only A leading global, innovative developer and manufacturer of medical devices for: Monitoring neurological Ultrasonic monitoring of Diagnosing disorders including long- Highly sophisticated blood flow through the sleep disorders term epilepsy monitoring brain r
Slide 5: FY2018 – Performance Review
FY2018 – Performance Review For personal use only ▪ FY18 Revenue (reported) $37.0m, EBITDA (reported) $4.2m, NPAT (reported) $2.8m FY18 FY17 Variance Comment Sales growth across key international markets for Revenue - reported $37.0m $34.4m 8% the core business, including China, Europe, DWL and US.
Slide 6: FY2018 – Performance Review
FY2018 – Performance Review For personal use only ▪ Core: US business grows 8%, albeit at slower rates than expected. Europe and DWL also grow in FY18, compared to FY17 ▪ Core: Asia business and China in particular strong with 28% lift in sales over pcp. ▪ Core: Profitability grows as a result of th
Slide 7: Sales Bridge Chart – FY17 to FY18
Sales Bridge Chart – FY17 to FY18 For personal use only 40 35 30 25 20 15 10 5 0 Sales FY17 USA Aust Asia Europe Sales FY18 Fall Rise 7
Slide 8: EBITDA Bridge Chart – FY17 to FY18
EBITDA Bridge Chart – FY17 to FY18 For personal use only 6 5 4 3 2 1 0 EBITDA FY17 Sales Margin Expenses Other FX EBITDA FY18 Revenues Fall Rise 8
Slide 9: Revenue Composition at $37.0m June 2018
Revenue Composition at $37.0m 30 June 2018 For personal use only By geographic region By product/market Tech. Supply Service, Europe, Items, 9% 9% 21% Brain USA, 32% Blood Flow, 17% Sleep, 33% Brain Res, Asia, 33% Aust, 14% 18% Neuro, 14% Software upgrades 5 to 10% of system sales Compumedics sells
Slide 10: Growth Platform – Core and Step-Out
Growth Platform – Core and Step-Out For personal use only Sales – schematic only FY18A FY19F FY20F FY21F FY22F Core - Base Core - Sleep/Neuro (Mid Market) Neuro - MEG Sleep - eHealth (Nexus360 & Somfit) • Step-out - NEURO – BRAIN IMAGING – Installation at Barrow Neurological Institute in Phoenix, AZ
Slide 11: Core Business – Premium Focus
Core Business – Premium Focus For personal use only Neuro Sleep Neuro Brain Blood Diagnostics – Diagnostics Diagnostics - Research Flow Diagnostics Clinic Global market – 250m 1,300m 20m 15m USD pa Compumedics market share 6% <1% 30% 35% (approximate) Aust – 1 Aust – 1 Aust – 1 Aust – 1 Compumedics
Slide 12: Core Business – Growing revenues and profits
Core Business – Growing revenues and profits For personal use only 40,000 6,000 35,000 5,000 30,000 4,000 25,000 3,000 20,000 2,000 15,000 1,000 10,000 - 5,000 -1,000 - -2,000 2012 2013 2014 2015 2016 2017 2018 Revenues EBITDA 1.2000 AUD/USD exchange rate 1.0324 1.0271 1.0000 0.9188 0.8386 0.7426 0.
Slide 13: Core Business – Net Cash Position maintained
Core Business – Net Cash Position maintained For personal use only $m FY12 FY13 FY14 FY15 FY16 FY17 FY18 Cash 1.1 1.3 1.1 2.2 3.1 4.1 3.9 Trade receivables 8.7 8.1 8.6 9.8 11.9 13.1 18.3 Inventories 5.3 5.5 6.1 5.7 6.5 7.4 7.6 Prod. dev’t 4.0 3.5 2.9 2.7 2.4 2.4 4.0 Tax asset 0.0 0.0 0.0 0.0 0.5 0.8
Slide 14: Core Business – Adding Mid-Tier Range
Core Business – Adding Mid-Tier Range For personal use only Average Product Used for Bought by selling price Sleep and neurology, high end and Hospitals, doctors USD11,500 to Grael family price sensitive models and service providers USD17,500 Hospitals, doctors Somte PSG Sleep USD10,000 and service
Slide 15: Next Generation Growth – Core and Step-out
Next Generation Growth – Core and Step-out For personal use only Neuro Sleep Neuro Brain Blood Diagnostics – Diagnostics Diagnostics - Imaging Flow Diagnostics Clinic Cloud based sleep Long term epilepsy Leverage existing TCD Leverage CURRY Next generation diagnostic platforms for market penetration
Slide 16: Core Business - Growth Drivers
Core Business - Growth Drivers For personal use only Compumedics/NeuroScan LTEM innovative brain analysis software and high performance amplifiers are unrivalled world class technology. With the release of new innovative electrode array designs, a larger growth is anticipated in direct sales, with a
Slide 17: USA Clinical Sales Force Expansion
USA – CMP is number 3 Supplier USA Clinical Sales Force Expansion - Indicative For personal use only More sales representatives = more revenue for both sleep and neurology Past USD3.0m FY2018 to now USD4.0m FY2019 USD7.0m FY2020 USD11.0m 17
Slide 18: China - We are the number Premier Supplier
China - We are the number 1 Premier Supplier Compumedics Clients in China For personal use only Sleep Neuroscience Neuroscan 28 2 Xin Jiang 5 Helongjiang Inner Mongolia 2 Jilin Beijing 88 2 Liaoning Ningxia 23 Qinhuangdao China Sales (invoiced) – USD’s QingHai 3 HeBei 10 3 Tianjin Dalian 2 3 16 12 7
Slide 19: Step out - Brain Imaging: 1st sale secured
Step out 1 - Brain Imaging: 1st sale secured For personal use only Opportunity Market & Competition Plan Outcome CMP’s CURRY brain analysis The MEG market is currently estimated H1 FY19 – complete first CMP plans to sell software is already the gold at about 20 systems a year at an installation at U
Slide 20: Step out - eHealth – Cloud Sleep Diagnostics
Step out 2 - eHealth – Cloud Sleep Diagnostics For personal use only Nexus 360 Operational systems have been Compumedics are now Key partners (professional cloud developed for the cloud based approaching being pursued sleep diagnostics) capture, transfer a select group of continue to sold into 16 US
Slide 21: Directors & Executive Team
Directors & Executive Team Key Management For personal use only David Burton, Ph.D. Executive Chairman, CEO Founder, Tenure 31yrs Alan Anderson Ph.D. Mr Tucson Dunn Mr. David Lawson Non Executive Director Non Executive Director Chief Financial Officer CMP Tenure : 18 yrs CMP Tenure 6 months & Compan
Slide 22: Investor Summary
Investor Summary Core business profitable with on-going growth For personal use only opportunities in key global markets International sales force Compumedics remains committed expansion, neurology and sleep to continuing to deliver superior market opportunity and earnings returns to shareholders im
Slide 23: Meeting closes
Meeting closes For personal use only Refreshments are available in the main reception area, where additional questions and discussion are encouraged, for those who are interested. 23
Slide 24: Disclaimer
Disclaimer For personal use only This presentation has been prepared by Compumedics Ltd (CMP). While the information in this presentation has been prepared in good faith and with reasonable care, no representation or warranty, express or implied, is made as to the accuracy, adequacy or reliability o
Slide 25: compumedics.com.au
For personal use only compumedics.com.au 25